Immix Biopharma (IMMX) Notes Payables (2020 - 2022)
Quarterly results put Notes Payables at $50000.0 for Q1 2022, changed N/A from a year ago — trailing twelve months through Mar 2022 was $50000.0 (changed N/A YoY), and the annual figure for FY2021 was $50000.0, changed 0.0%.
Immix Biopharma has reported Notes Payables over the past 3 years, most recently at $50000.0 for Q1 2022.
- Notes Payables reached $50000.0 in Q1 2022 per IMMX's latest filing, roughly flat from $50000.0 in the prior quarter.
- Across five years, Notes Payables topped out at $50000.0 in Q4 2020 and bottomed at $50000.0 in Q4 2020.
- Median Notes Payables over the past 3 years was $50000.0 (2020), compared with a mean of $50000.0.
- Peak annual rise in Notes Payables hit 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
- Over 3 years, Notes Payables stood at $50000.0 in 2020, then changed by 0.0% to $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022.
- Business Quant data shows Notes Payables for IMMX at $50000.0 in Q1 2022, $50000.0 in Q4 2021, and $50000.0 in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 50,000.00 |
| Dec 31, 2021 | 50,000.00 |
| Dec 31, 2020 | 50,000.00 |